The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26

Amino Acids

Volumn 41, Issue 4, 2011, Pages 909-921

  Kotsakis, Panayiotis ^a,b   Wang, Zhuo ^a   Collighan, Russell John ^a   Griffin, Martin ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

3 integrins; Colon cancer; Metastasis; TGF 1; Tissue transglutaminase

Indexed keywords

BETA3 INTEGRIN; DOXORUBICIN; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COLON CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION;

ANIMALS; ANTIGENS, CD29; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; DOXORUBICIN; EXTRACELLULAR MATRIX; FEMALE; FIBRONECTINS; GTP-BINDING PROTEINS; INTEGRIN BETA CHAINS; INTEGRIN BETA3; MICE; MICE, INBRED BALB C; NF-KAPPA B; SYNDECAN-4; TRANSFORMING GROWTH FACTOR BETA1; TRANSGLUTAMINASES;

EID: 83255193504     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-010-0790-1     Document Type: Article

References (49)

1. Ai LB, Kim WJ, Demircan B, Dyer LM, Bray KJ, Skehan RR, Massoll NA, Brown KD (2008) The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 29:510-518
2. Akimov SS, Belkin AM (2001) Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatinbinding domain of fibronectin: a role in TGF beta-dependent matrix deposition. J Cell Sci 114:2989-3000
3. Akimov SS, Belkin AM (2003) Opposing roles of Ras/Raf oncogenes and the MEK1/ERK signaling module in regulation of expression and adhesive function of surface transglutaminase. J Biol Chem 278:35609-35619
4. Akimov SS, Krylov D, Fleischman LF, Belkin AM (2000) Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 148:825-838
5. Antonyak MA, Li B, Regan AD, Feng Q, Dusaban SS, Cerione RA (2009) Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J Biol Chem 284:17914-17925
6. Balklava Z, Verderio E, Collighan R, Gross S, Adams J, Griffin M (2002) Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but is important for its secretion. J Biol Chem 277:16567-16575
7. Barnes RN, Bungay PJ, Elliott BM, Walton PL, Griffin M (1985) Alterations in the distribution and activity of transglutaminase during tumour growth and metastasis. Carcinogenesis 6:459-463
8. Belkin AM, Zemskov EA, Hang J, Akimov SS, Sikora S, Strongin AY (2004) Cell-surface-associated tissue transglutaminase is a target of MMP-2 proteolysis. Biochemistry 43:11760-11769
9. Chau DYS, Collighan RJ, Verderio EAM, Addy VL, Griffin M (2005) The cellular response to transglutaminase-cross-linked collagen. Biomaterials 26:6518-6529
10. Collighan RJ, Griffin M (2009) Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids 36:659-670
11. Di Giacomo G, Lentini A, Beninati S, Piacentini M, Rodolfo C (2009) In vivo evaluation of type 2 transglutaminase contribution to the metastasis formation in melanoma. Amino Acids 36:717-724
12. Fisher M, Jones RA, Huang L, Haylor JL, El Nahas M, Griffin M, Johnson TS (2009) Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring. Matrix Biol 28:20-31
13. Gaudry CA, Verderio E, Aeschlimann D, Cox A, Smith C, Griffin M (1999) Cell surface localization of tissue transglutaminase is dependent on a fibronectin-binding site in its N-terminal betasandwich domain. J Biol Chem 274:30707-30714
14. Griffin M, Casadio R, Bergamini CM (2002) Transglutaminases: Nature's biological glues. Biochem J 368:377-396
15. Griffin M, Mongeot A, Collighan R, Saint RE, Jones RA, Coutts IGC, Rathbone DL (2008) Synthesis of potent water-soluble tissue transglutaminase inhibitors. Bioorg Med Chem Lett 18:5559- 5562.
16. Grigoriev MY, Suspitsin EN, Togo AV, Pozharisski KM, Ivanova OA, Nardacci R, Falasca L, Piacentini M, Imyanitov EN, Hanson KP (2001) Tissue transglutaminase expression in breast carcinomas. J Exp Clin Cancer Res 20:265-268
17. Gundemir S, Johnson GV (2009) Intracellular localization and conformational state of transglutaminase 2: implications for cell death. PLoS One 4:e6123
18. Hand D, Elliott BM, Griffin M (1988) Expression of the cytosolic and particulate forms of transglutaminase during chemically induced rat liver carcinogenesis. Biochim Biophys Acta 970:137-145
19. Herman JF, Mangala LS, Mehta K (2006) Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25:3049-3058
20. Huang LH, Haylor JL, Hau Z, Jones RA, Vickers ME, Wagner B, Griffin M, Saint RE, Coutts IGC, El Nahas AM, Johnson TS (2009) Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int 76:383-394
21. Ientile R, Caccamo D, Griffin M (2007) Tissue transglutaminase and the stress response. Amino Acids 33:385-394
22. Johnson TS, Knight CR, el-Alaoui S, Mian S, Rees RC, Gentile V, Davies PJ, Griffin M (1994) Transfection of tissue transglutaminase into a highly malignant hamster fibrosarcoma leads to a reduced incidence of primary tumour growth. Oncogene 9:2935-2942
23. Johnson TS, Fisher M, Haylor JL, Hau Z, Skill NJ, Jones R, Saint R, Coutts I, Vickers ME, El Nahas AM, Griffin M (2007) Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol 18:3078-3088
24. Jones RA, Nicholas B, Mian S, Davies PJ, Griffin M (1997) Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin. J Cell Sci 110:2461-2472
25. Jones RA, Kotsakis P, Johnson TS, Chau DY, Ali S, Melino G, Griffin M (2006) Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ 13:1442-1453
26. Knight CR, Rees RC, Griffin M (1990) Reduction in transglutaminase activity associated with tumour metastasis is due to the presence of an inactive form of the enzyme. Biochem Soc Trans 18:681-682
27. Kotsakis P, Griffin M (2007) Tissue transglutaminase in tumour progression: friend or foe? Amino Acids 33:373-384
28. Lentini A, Abbruzzese A, Caraglia M, Marra M, Beninati S (2004) Protein-polyamine conjugation by transglutaminase in cancer cell differentiation: review article. Amino Acids 26:331-337
29. Lorand L, Campbell-Wilkes LK, Cooperstein L (1972) A filter paper assay for transamidating enzymes using radioactive amine substrates. Anal Biochem 50:623-631
30. Mangala LS, Arun B, Sahin AA, Mehta K (2005) Tissue transglutaminase- induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer 4:1-8
31. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal BB, Mehta K (2006) Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res 66:8788-8795
32. Mehta K (2009) Biological and therapeutic significance of tissue transglutaminase in pancreatic cancer. Amino Acids 36:709- 716.
33. Myrsky E, Caja S, Simon-Vecsei Z, Korponay-Szabo IR, Nadalutti C, Collighan R, Mongeot A, Griffin M, Maki M, Kaukinen K, Lindfors K (2009) Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA. Cell Mol Life Sci 66:3375-3385
34. Nicholas B, Smethurst P, Verderio E, Jones R, Griffin M (2003) Cross-linking of cellular proteins by tissue transglutaminase during necrotic cell death: a mechanism for maintaining tissue integrity. Biochem J 371:413-422
35. Piacentini M, Piredda L, Starace DT, Annicchiarico-Petruzzelli M, Mattei M, Oliverio S, Farrace MG, Melino G (1996) Differential growth of N- and S-type human neuroblastoma cells xenografted into scid mice. Correlation with apoptosis. J Pathol 180:415-422
36. Rosenkranz S (2004) TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63:423-432
37. Shweke N, Boulos N, Jouanneau C, Vandermeersch S, Melino G, Dussaule JC, Chatziantoniou C, Ronco P, Boffa JJ (2008) Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol 173:631-642
38. Smethurst PA, Griffin M (1996) Measurement of tissue transglutaminase activity in a permeabilized cell system: its regulation by Ca2+ and nucleotides. Biochem J 313:803-808
39. Switala-Jelen K, Dabrowska K, Opolski A, Lipinska L, Nowaczyk M, Gorski A (2004) The biological functions of beta3 integrins. Folia Biol (Praha) 50:143-152
40. Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM, Ginsberg MH, Calderwood DA (2003) Talin binding to integrin beta tails: a final common step in integrin activation. Science 302:103-106
41. Telci D, Wang Z, Li X, Verderio EA, Humphries MJ, Baccarini M, Basaga H, Griffin M (2008) Fibronectin-tissue transglutaminase matrix rescues RGD-impaired cell adhesion through syndecan-4 and beta1 integrin co-signaling. J Biol Chem 283:20937-20947
42. Telci D, Colligha RJ, Basaga H, Griffin M (2009) Increased TG2 expression can result in induction of transforming growth factor beta 1, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide. J Biol Chem 284:29547-29558
43. Toth B, Sarang Z, Vereb G, Zhang AL, Tanaka S, Melino G, Fesus L, Szondy Z (2009) Over-expression of integrin beta 3 can partially overcome the defect of integrin beta 3 signaling in transglutaminase 2 null macrophages. Immunol Lett 126:22-28
44. Verderio E, Nicholas B, Gross S, Griffin M (1998) Regulated expression of tissue transglutaminase in Swiss 3T3 fibroblasts: effects on the processing of fibronectin, cell attachment, and cell death. Exp Cell Res 239:119-138
45. Verderio E, Gaudry C, Gross S, Smith C, Downes S, Griffin M (1999) Regulation of cell surface tissue transglutaminase: effects on matrix storage of latent transforming growth factor-beta binding protein-1. J Histochem Cytochem 47:1417-1432
46. Verderio EA, Telci D, Okoye A, Melino G, Griffin M (2003) A novel RGD-independent cell adhesion pathway mediated by fibronectin- bound tissue transglutaminase rescues cells from anoikis. J Biol Chem 278:42604-42614
47. Verma A, Mehta K (2007a) Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Update 10:144-151
48. Verma A, Mehta K (2007b) Transglutaminase-mediated activation of nuclear transcription factor-kappa B in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets 7:559-565
49. Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, Piwnica-Worms D, Rich KM (2007) Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 26:2563-2573